Search | IOVS | ARVO Journals

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Onset of Improvement in Signs and Symptoms of Vernal Keratoconjunctivitis (VKC) in Patients Treated with Cyclosporine A Cationic Emulsion (CsA CE) in the NOVATIVE Study

Andrea Leonardi; Serge Doan; Pierre-Jean Pisella; Mourad Amrane; Dahlia Ismail; Dominique Bremond-Gignac

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):892 – A0256. doi:

ARVO Annual Meeting Abstract July 2019

Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials

Dominique Bremond-Gignac; Pasquale Aragona; Serge Doan; Mourad Amrane; DAHLIA ISMAIL; Jesús Montero; János Németh; Andrea Leonardi

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6710. doi:

ARVO Annual Meeting Abstract July 2018

A longitudinal study of the relationship between signs and symptoms in keratoconjunctivitis sicca

Jeffry Hogg; Dahlia Ismail; Jean-Sebastien Garrigue; Maëva Deniaud; Mourad Amrane; Francisco C Figueiredo

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):934. doi:

ARVO Annual Meeting Abstract July 2018

Topical Cyclosporine A 1 mg/mL Cationic Emulsion Yields Improvements in Signs of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Serge Doan; Andrea Leonardi; Mourad Amrane; Dahlia Ismail; Jesus Montero; Pasquale Aragona; Janos Nemeth; Dominique Brémond-Gignac

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5572. doi:

ARVO Annual Meeting Abstract June 2017

Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Andrea Leonardi; Serge Doan; Mourad Amrane; Dahlia Ismail; Jesus Montero; VVL Narasimha Rao; Janos Nemeth; Dominique Bremond-Gignac

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):541. doi:

Cornea April 2017

Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease

PDF

Françoise Brignole-Baudouin; Luisa Riancho; Dahlia Ismail; Maëva Deniaud; Mourad Amrane; Christophe Baudouin
TAGS: dry eye syndromes, hla-dr antigens, signs and symptoms, inflammatory markers
Invest. Ophthalmol. Vis. Sci.. 2017; 58(4):2438-2448. doi: https://doi.org/10.1167/iovs.15-16555

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: Experience through the French early access program

Serge Doan; Pierre-Jean Pisella; Beatrice Cochener; Mourad Amrane; Dahlia Ismail; Christophe Baudouin; Marc Labetoulle

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2876. doi:

ARVO Annual Meeting Abstract September 2016

Safety and efficacy of ciclosporin 1 mg/mL cationic emulsion (CsA CE) over 12 months in patients with severe dry eye disease (DED) in the SANSIKA Phase III trial

Gysbert B Van Setten; Francisco C Figueiredo; Andrea Leonardi; Mourad Amrane; Jean-Sebastien Garrigue; Dahlia Ismail; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2865. doi:

ARVO Annual Meeting Abstract September 2016

Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED)

Elisabeth Messmer; Andrea Leonardi; Mourad Amrane; Dahlia Ismail; Francisco C Figueiredo; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2871. doi:

ARVO Annual Meeting Abstract June 2015

Correlation between the Inflammatory Marker HLA DR and Signs and Symptoms in moderate to severe Dry Eye Disease

Christophe Baudouin; Hong Liang; Luisa RIANCHO; Dahlia Ismail; Maeva Deniaud; Mourad Amrane; Francoise Brignole-Baudouin

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):298. doi:

ARVO Annual Meeting Abstract June 2015

Patients with Moderate to Severe Dry Eye Disease in Routine Clinical Practice in the UK - Physician and Patient’s Assessments

Mourad Amrane; Alexandre CIVET; Alexandre Templier; Dian Kang; Francisco C Figueiredo

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4443. doi:

ARVO Annual Meeting Abstract March 2012

The Effect of Cyclokat® (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial

Ronald R. Buggage; Mourad Amrane; Dahlia Ismail; Maeva Deniaud; Michael A. Lemp; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):576. doi:

ARVO Annual Meeting Abstract March 2012

The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion

Mourad Amrane; Andrea Leonardi; Dominique Bremond-Gignac; Maeva Deniaud; Dahlia Ismail; Christophe Baudouin; Ronald Buggage

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4011. doi:

ARVO Annual Meeting Abstract April 2011

Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial

Michael A. Lemp; Christopher Baudouin; Mourad Amrane; Dahlia Ismail; Jean Sebastien Garrigue; Ronald R. Buggage

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3821. doi:

ARVO Annual Meeting Abstract April 2011

A Multicenter, Double-masked, Randomized, Parallel Group, Controlled Trial Of Efficacy And Tolerance Of NOVA22007 (Cyclosporine Cationic Emulsion) Versus Vehicle In Patients With Vernal Keratoconjunctivitis

Mourad Amrane; Dominique Bremond-Gignac; Christopher Baudouin; Andrea Leonardi; Maeva Deniaud; Ronald Buggage

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6415. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Onset of Improvement in Signs and Symptoms of Vernal Keratoconjunctivitis (VKC) in Patients Treated with Cyclosporine A Cationic Emulsion (CsA CE) in the NOVATIVE Study

Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials

A longitudinal study of the relationship between signs and symptoms in keratoconjunctivitis sicca

Topical Cyclosporine A 1 mg/mL Cationic Emulsion Yields Improvements in Signs of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study

Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease

Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: Experience through the French early access program

Safety and efficacy of ciclosporin 1 mg/mL cationic emulsion (CsA CE) over 12 months in patients with severe dry eye disease (DED) in the SANSIKA Phase III trial

Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED)

Correlation between the Inflammatory Marker HLA DR and Signs and Symptoms in moderate to severe Dry Eye Disease

Patients with Moderate to Severe Dry Eye Disease in Routine Clinical Practice in the UK - Physician and Patient’s Assessments

The Effect of Cyclokat® (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial

The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion

Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial

A Multicenter, Double-masked, Randomized, Parallel Group, Controlled Trial Of Efficacy And Tolerance Of NOVA22007 (Cyclosporine Cationic Emulsion) Versus Vehicle In Patients With Vernal Keratoconjunctivitis

To View More...

You must be signed into an individual account to use this feature.